TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28605206

Group type: EXPERIMENTAL
Intervention: Holistic self-management plan (four educational sessions and three personal home sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Short manual with asthma information (control group)
Number of subjects: 24
Study: 25589624

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib (60 mg orally once daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclophosphamide alone (50 mg orally once daily)
Number of subjects: 75
Study: 23936331

Group type: EXPERIMENTAL
Intervention: Urinary betaine excretion in patients with diabetes mellitus (n = 264)
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Urinary betaine excretion
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Baseline betaine excretion
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 2396
Study: 21882087

Group type: EXPERIMENTAL
Intervention: Low-contrast dose protocol (P(low)): iohexol-350 [0.7 ml/kg body weight (BW)] during 9 s
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional protocol (P(conv)): iohexol-350 (1.0 ml/kg BW) during 15 s
Number of subjects: 60
Study: 18710401

Group type: COMPARATOR
Intervention: Mandibular free-end removable partial denture wearers (group II)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maxillary and mandibular complete denture wearers (group I)
Number of subjects: 28
Study: 17266094

Group type: EXPERIMENTAL
Intervention: Trial participants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trial nonparticipants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients with diabetes
Number of subjects: 40
Study: 15193740

Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg (formulation 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gliclazide 80 mg (formulation 2)
Number of subjects: 20
Study: 11331167

Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib capsule po 1 hour before induction of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsule po 1 hour before induction of anesthesia
Number of subjects: 0
Study: 9154397

Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% solution
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 7700076

Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: cilazapril 5.0 mg once daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 3688394

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trichloroethylene
Number of subjects: 60
Study: 29352454

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 27001782

Group type: EXPERIMENTAL
Intervention: Vibrating massage of all masseter muscles, tourmaline ceramic on the joint area, and local physical therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine blockade of periarticular area (control group).
Number of subjects: 0
Study: 26509174

Group type: EXPERIMENTAL
Intervention: Vitamin C, vitamin E, and zinc supplementation for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23437055

Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine at 10 μg/dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine at 50 μg/dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine (both doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine (high dose)
Number of subjects: 24
Study: 20008820

Group type: EXPERIMENTAL
Intervention: Partnered tango dance
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonpartnered tango dance
Number of subjects: 39
Study: 18834276

Group type: EXPERIMENTAL
Intervention: Group therapy for complicated grief
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Expression of positive emotion as a mediator
Number of subjects: 107
Study: 16402602

Group type: EXPERIMENTAL
Intervention: Complexity-based estimators of heart rate variability (detrended fluctuation analysis coefficient, sample entropy, largest Lyapunov exponent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional measures of heart rate variability
Number of subjects: 0
Study: 12953347

Group type: EXPERIMENTAL
Intervention: CHF 3381 (25, 50, 100, 200, 300, 450, and 600 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF 3381 (600 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF 3381 (various doses)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF 3381 (300 and 600 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF 3381 (200 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF 3381 (300 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Food ingestion
Number of subjects: 56
Study: 10962546

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (20 mg daily subcutaneous injection)
Number of subjects: 251
Study: 8722342

Group type: EXPERIMENTAL
Intervention: Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy2) preparative regimen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard cyclosporine and methotrexate or cyclosporine and methylprednisolone for GVHD prophylaxis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide (BuCy2)
Number of subjects: 26
Study: 1730131

Group type: EXPERIMENTAL
Intervention: Later intervention (LI)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Early intervention (EI)
Number of subjects: 205
Study: 3901832

Group type: EXPERIMENTAL
Intervention: 12-hour theophylline preparation (Theo-Dur)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 24-hour theophylline preparation (Theo-24)
Number of subjects: 20
Study: 31184720

Group type: EXPERIMENTAL
Intervention: Extracorporeal Membrane Oxygenation (ECMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 29381569

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion therapy (3 mg/kg) administered once a week for 4 consecutive weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline infusions (control group) administered once a week for 4 consecutive weeks
Number of subjects: 42
Study: 26361380

Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Full Sleep
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both Sleep Conditions
Number of subjects: 16
Study: 25699349

Group type: EXPERIMENTAL
Intervention: Voluven 7 ml/kg in 20 mins before induction and 8 ml/kg after induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plasmalyte A 6 ml/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Voluven
Number of subjects: 40
Study: 22856218

Group type: EXPERIMENTAL
Intervention: Hyperbaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 10% glucose)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypobaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 0.9% NaCl)
Number of subjects: 110
Study: 21313917

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg per 4 h up to 3 days)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal suppositories
Number of subjects: 111
Study: 18019402

Group type: EXPERIMENTAL
Intervention: Valacyclovir at 14.3 mg/kg every 6 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study: 16615261

Group type: EXPERIMENTAL
Intervention: Insulin infusion (intervention group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (prior to insulin infusion)
Number of subjects: 103
Study: 14669937

Group type: EXPERIMENTAL
Intervention: 7.75% carbohydrate solution
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 7.75% carbohydrate/1.94% protein solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10947748

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1) with neostigmine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1) without neostigmine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg x kg(‐1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1)
Number of subjects: 3
Study: 8773908

Group type: EXPERIMENTAL
Intervention: Interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months (Group 1)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months (Group 2)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment or different duration)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall treatment with interferon
Number of subjects: 116
Study: 1537998

Group type: EXPERIMENTAL
Intervention: Accelerated rt‐PA (1.25 mg/kg over 90 min, regimen C)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Exaggerated (60‐min) dosage regimen
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Combination therapy (accelerated rt‐PA and intravenous urokinase, regimen E)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Conventional 3‐h dosing regimens
Number of subjects: 232
Study: 6462423

Group type: EXPERIMENTAL
Intervention: MS subjects using a semantic encoding strategy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MS subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 22
Study: 31291159

Group type: EXPERIMENTAL
Intervention: Loud vocal SPL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Spontaneous vocal SPL
Number of subjects: 32
Study: 29061222

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT) - high-frequency sessions (3 sessions per week)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT) - low-frequency sessions (1 session per week)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Enhanced standard care (ESC) alone
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT)
Number of subjects: 364
Study: 25822648

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs (40 × 10^6 cells, intra-articular injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyaluronic acid (60 mg, single dose, intra-articular)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs
Number of subjects: 30
Study: 23360149

Group type: EXPERIMENTAL
Intervention: Aft cleat position
Number of subjects: 13

Group type: COMPARATOR
Intervention: Traditional cleat position
Number of subjects: 13
Study: 22086695

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5μg/kg/wk for 23 months (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5μg/kg/wk for 11 months (group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All patients (combined analysis)
Number of subjects: 18
Study: 19519822

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP+)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No intervention (IP‐)
Number of subjects: 75
Study: 17689947

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/100 microg bd
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg bd
Number of subjects: 4
Study: 15288592

Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg/day plus piperazine-sultosilate 1000 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: pravastatin 40 mg/day
Number of subjects: 26
Study: 11696941

Group type: EXPERIMENTAL
Intervention: Individualized criteria for monitoring heart rate and oxygen saturation during gentle human touch (GHT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard criteria for monitoring heart rate and oxygen saturation
Number of subjects: 0
Study: 9441096

Group type: EXPERIMENTAL
Intervention: Severe pulmonary tuberculosis (SPT) patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (PT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 17
Study: 8202005

Group type: EXPERIMENTAL
Intervention: Single-dose prednisolone
Number of subjects: 64
Study: 3479045

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g) administered at 12-hour intervals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered at 12-hour intervals
Number of subjects: 8
Study: 30120004

Group type: EXPERIMENTAL
Intervention: Individual aberration‐correcting IOL (Invidua‐aA; Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard aspheric aberration‐free IOL (Aspira‐aA; Group B)
Number of subjects: 86
Study: 27020075

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 122
Study: 26581842

Group type: EXPERIMENTAL
Intervention: Atorvastatin (oral 20 mg/night for 8 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (dextrin for 8 weeks)
Number of subjects: 96
Study: 23738908

Group type: EXPERIMENTAL
Intervention: 3 mL of EMLA cream (5% lidocaine 25 mg‐prilocaine 25 mg/g)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 3 mL of ultrasound gel (placebo)
Number of subjects: 92
Study: 20684147

Group type: EXPERIMENTAL
Intervention: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g) for 52 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two-compound ointment alternating with calcipotriene four-weekly
Number of subjects: 24

Group type: COMPARATOR
Intervention: Betamethasone 0.5 mg/g (as dipropionate; Diprosone) ointment
Number of subjects: 24
Study: 18305085

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both SES and BMS
Number of subjects: 42
Study: 16941299

Group type: EXPERIMENTAL
Intervention: 200 units Botulinum toxin A (BoNT A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 units Botulinum toxin A (BoNT A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 12923616

Group type: EXPERIMENTAL
Intervention: Sufentanil (initial bolus 0.5 micro g/kg and continuous infusion rate of 0.5 micro g/kg per hour)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam (initial bolus 0.08 mg/kg and continuous infusion 0.05 mg/kg per hour)
Number of subjects: 10
Study: 10875787

Group type: EXPERIMENTAL
Intervention: Oral BCG vaccination (double-dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intradermal BCG booster vaccination
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral BCG vaccination
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9083231

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 33
Study: 8239321

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 4
Study: 3752219

Group type: EXPERIMENTAL
Intervention: Purposeful activities
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpurposeful activities
Number of subjects: 30
Study: 29265833

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Feedback on symptomatology
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Feedback on the alliance
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Feedback on both symptomatology and alliance
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Lambert's OQ progress feedback report
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Positive feedback (low symptomatology)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Negative feedback (high symptomatology)
Number of subjects: 547
Study: 28384828

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 379
Study: 25117853

Group type: EXPERIMENTAL
Intervention: Vigabatrin 1 g/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vigabatrin 3 g/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vigabatrin 6 g/day
Number of subjects: 5
Study: 23835026

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) after intravenous thrombolysis (IVT)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Optimal medical care alone
Number of subjects: 750
Study: 21993064

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (10 ml of 0.2%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cacao bean husk extract mouthrinse (10 ml of 0.1%)
Number of subjects: 50
Study: 18785254

Group type: EXPERIMENTAL
Intervention: Atrasentan 10 mg daily
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study: 16541325

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: Ovarian ablation by oophorectomy
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 317
Study: 12925248

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day for 72 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 to 80 mg intravenously during surgery)
Number of subjects: 34
Study: 11004140

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 8666957

Group type: EXPERIMENTAL
Intervention: Unidimensional rating task preceding pairwise dissimilarity ratings
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 3-s delay between presentation of pair members
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Global effects of density modeled by extending A. Parducci's range-frequency theory
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Local density effects
Number of subjects: 3
Study: 1296466

Group type: EXPERIMENTAL
Intervention: Instructional programme intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-placebo group
Number of subjects: 0
Study: 6150902

Group type: EXPERIMENTAL
Intervention: salbutamol (300 micrograms/60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: salbutamol (600 micrograms/60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: prenalterol (1 mg/60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: prenalterol (2 mg/60 min)
Number of subjects: 6
Study: 31609774

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 250
Study: 29129457

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS) 18‐21 mmHg at the ankle level (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo stocking (0 mmHg, n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo stocking
Number of subjects: 30
Study: 27842163

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy (Bevacizumab and Ranibizumab) administered monthly for 6 months
Number of subjects: 89
Study: 23793234

Group type: EXPERIMENTAL
Intervention: Exercise training (n = 72)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (n = 68)
Number of subjects: 140
Study: 22215059

Group type: EXPERIMENTAL
Intervention: Methylene blue
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 58
Study: 20724937

Group type: EXPERIMENTAL
Intervention: Controlled hypertension
Number of subjects: 31495

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 31495

Group type: EXPERIMENTAL
Intervention: Common mental disorder (GHQ-12 score of ≥4)
Number of subjects: 31495

Group type: EXPERIMENTAL
Intervention: Diagnosed hypertension with common mental disorder
Number of subjects: 31495

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension with common mental disorder
Number of subjects: 31495

Group type: EXPERIMENTAL
Intervention: Undiagnosed (untreated) hypertension with common mental disorder
Number of subjects: 31495
Study: 17954953

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 157
Study: 15808167

Group type: EXPERIMENTAL
Intervention: Microsil IOL with a sharp optic edge design (model S)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Microsil IOL with a round optic edge design (model R)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both IOL groups
Number of subjects: 51
Study: 12160813

Group type: EXPERIMENTAL
Intervention: 5 mL lignocaine 2% with sodium hyaluronidase 150 IU/mL
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 mL plain lignocaine 2%
Number of subjects: 100
Study: 11562930

Group type: EXPERIMENTAL
Intervention: Genetic Counselor
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Interactive Computer Program
Number of subjects: 29
Study: 9129047

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 100 microg/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 50 microg/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 9
Study: 7893592

Group type: EXPERIMENTAL
Intervention: Post tetracosactrin levels of plasma and salivary cortisol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post CRH-LVP levels of plasma ACTH and LPH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline levels of 08.00 h salivary cortisol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline levels of 08.00 h plasma cortisol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post metyrapone levels of plasma 11-deoxycortisol, ACTH, LPH and beta-endorphin
Number of subjects: 20